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Objectives: The objectives were to assess experiences of menstrual bleeding and nonbleeding side effects among
current and past users of injectables and implants and the associations between side effects and method evalu-
ations by women — satisfaction, perceived suitability, the likelihood of future use and intended duration of use.
Study design:We used data on past and current users of injectables and implants from a survey of 1866married or
cohabiting women who participated in the third round of a 2-year prospective longitudinal study conducted in
Homa Bay County, Western Kenya. Descriptive and bivariate analysis with χ2 tests was used to assess statistically
significant associations between experience of bleeding/nonbleeding side effects and method-specific attitudes.
Results: Self-reported method-related bleeding problems were high among current and past users of injectables
(range 69%–79%) and implants (range 55%–60%) and much more common than nonbleeding side effects. For
both methods, experience of either bleeding or nonbleeding side effects reduces positive evaluations, but the con-
junction of both types had particularly pronounced consequences. Heavy bleeding was more strongly related to
method evaluation (satisfaction and the likelihood of future use; p b .001) among past users than other forms of
menstrual bleeding disorders. Even among current users, about one third regarded bleeding side effects as very se-
rious. Care-seeking fromahealthcare provider formanagement of contraceptive-related side effectswas lowamong
current users (less than 40%) and modest among past users (range 53%–63%).
Conclusions: The results underscore theneed to strengthenprograms on counseling and informationon contraceptive
side effects including menstrual bleeding disturbances to improve method satisfaction and reduce discontinuation.
Implication: Theexperience of contraceptive-relatedmenstrual bleeding andnonbleeding side effects reduces positive
evaluation of the method and deters past users from future use of the method.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Hormonal contraceptives are regarded as safe and highly efficacious;
however, side effects and health concerns may influence user's prefer-
ence, acceptability, method satisfaction, compliance and continuation
[1–5]. Changes in regular menstrual bleeding pattern (irregular bleed-
ing, heavy/prolonged bleeding, amenorrhea) have been clinically docu-
mented as major contraceptive side effects [3,6,7]. Bleeding and
nonbleeding side effects due to contraception and perceptions thereof
vary across individuals, methods and duration of use [1,8]. For instance,
intrauterine devices (IUDs) tend to be associated with heavy menstrual
bleeding and cramping, while injectables and implants are associated
with irregular menstruation and temporary amenorrhea [9,10]. Studies
have also documented women's negative experiences withonyango@popcouncil.org
a), John.Cleland@lshtm.ac.uk
nc. This is an open access article undcontraceptive-related bleeding problems and their adverse influence
on well-being [11–13].
While injectables and implants are themost widely used contracep-
tive methods in Kenya, they are plagued by high discontinuation rates.
The all-cause 12-month discontinuation of injectables is 31% but much
lower for implants at 8% [14]. Although evidence from theDemographic
and Health Surveys (DHSs) shows that side effects or health concerns
are major reasons for conceptive nonuse or discontinuation, their pre-
cise nature, perceived severity and consequences in low-income set-
tings are not well understood partly because DHSs use a broad
classification of side effects [15]. Thus, it remains uncertain whether a
woman's evaluation of a method, for instance, her satisfaction with it,
is influenced by the specific nature of bleeding or nonbleeding side ef-
fects. Few comparisons of experiences of side effects between current
and past users have been undertaken. Most studies focus on current
users' perspectives and ignore past users despite the fact that past
users comprise a high proportion of women with an unmet need for
family planning [16]. Moreover, a focus on current users may provide
a misleading impression because they may underreport side effectser the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Background characteristic of married or cohabiting women aged 15–39 who had ever
used injectables and/or implants at round three in Homa Bay, 2016
Characteristics Injectables
n (%)
Implants
n (%)
Age (years)
15–24 465 (30.8) 303 (38.3)
25–39 1047 (69.2) 489 (61.7)
Education
No schooling/some primary 653 (43.2) 341 (43.1)
Primary complete 506 (33.5) 268 (33.8)
Secondary or higher 353 (23.3) 183 (23.1)
Fertility preference
Want to soon/want within 2 years/undecided 227 (15.0) 110 (13.9)
Want no more 705 (46.6) 409 (51.6)
Want to wait 2 years or more 580 (38.4) 273 (34.5)
Method currently using at round 3
Injectables 558 (36.9) 145 (18.3)
Implants 341 (22.6) 424 (53.5)
Other methods 216 (14.3) 67 (8.5)
Not using 397 (26.3) 156 (19.7)
Total number of women [N]a 1512 (100.0) 792 (100.0)
a Ns does not sum to 1866 due to women being able to use more than one method.
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sociated with reporting menstrual bleeding problems [18].
In this paper, we assess experiences of menstrual bleeding and
nonbleeding side effects (such as headache, dizziness, weight loss/
gain, cramps) among current and past users of injectables and implants
and their associations withmethod-specific attitudes [satisfaction, suit-
ability, the likelihood of future use (past users) and length of intended
future use (current users) and care-seeking]. Understanding experi-
ences of method-related side effects is essential for improving contra-
ceptive counseling and information programs.
2. Data and methods
2.1. Study setting
Weused data from a third roundof a 2-year prospective longitudinal
study conducted in Homa Bay County, Western Kenya. The county is
predominantly rural and has a population of 1.3 million [19]. According
to the 2014 Kenya Demographic and Health Survey, Homa Bay County
has a high total fertility rate of 5.2 compared with a national average
of 3.9, a modest level of contraceptive use among currently married
women aged 15–49 years (47%) and a high unmet need for family plan-
ning at 26% [14]. Furthermore, the county has a perpetual burden of
high unintended pregnancy and overall high HIV prevalence estimated
at 21%, the second highest in Kenya [20]. These unfavorable sexual and
reproductive health indicators are partly due to poverty, weak health
systems, community beliefs and limited information on family planning
[21,22]. More information about the study design is published else-
where [23]. In summary, the aim of the study was to advance knowl-
edge on unmet need for family planning and unintended pregnancy,
including contraceptive uptake and continuation. It was observational
in nature, with no intervention.
2.2. Sample and data
The study targeted a sample of 2600 women to detect a 30% differ-
ence between women with contrasting baseline characteristics in re-
productive outcomes (pregnancy, use and nonuse of contraceptives)
between study rounds at 95% confidence level and 80% power consider-
ing a 45% attrition rate. A two-stage sampling approach was used. Stage
one involved selecting a random sample of 12 rural sublocations (the
smallest administrative unit in Kenya) with an equal probability from
three purposely selected subcounties: Rachuonyo North, Rachuonyo
South and Ndhiwa. All households with currently married or cohabiting
women aged 15–49 years were then identified, and a list of all individ-
uals in those householdswas generated to form a sampling frame. In the
second stage, a total of 3118 women aged 15–39 were randomly sam-
pled from among 5424 eligible women. Interviews were completed
with 2424 women during the first round (78% of those sampled),
2083 women during the second round (86% of those interviewed in
the round 1) and 1866 women during third round (91% of those
interviewed in round 2).
2.3. Measures
In all rounds, structured interviews that lasted on average 45 min
were conducted with eligible women in the local language (Dholuo)
by trained female interviewers using electronic-based data capture plat-
form, Open Data Kit (ODK). The questionnaire elicited information on
women's background, reproduction, sexual activity, fertility prefer-
ences, method-specific attitudes, satisfaction and experienceswith con-
traceptives (pill, injectable, implant, IUD and condoms). During the
third round, current and past users were asked to indicate if they had
experienced any effect on regular menses from using a specific method.
Those who reported experiencing any effect on regular menses were
further asked to indicate the most troubling problem (whether it wasno bleeding, irregular bleeding, heavy bleeding or any other bleeding
problems), its severity and whether they had sought advice or treat-
ment for the bleeding problem from a health provider. A similar se-
quence of questions was asked about nonbleeding side effects. The
study also sought women's opinions on overall satisfaction with the
method, the suitability of the method for someone like her, the likeli-
hood of future use (past users) and the length of intended use (current
users).2.4. Analysis
We used descriptive statistics (frequency and percentage distribu-
tion) and cross-tabulation with χ2 test to examine experiences of
method-related bleeding and nonbleeding side effects and their conse-
quences. We used p b .05 to indicate the statistical significance associa-
tions with 95% confidence intervals. All analysis was conducted using
Stata® version 15.1.3. Ethics approval and consent to participate
Ethical approvals for the study were granted by the Observational/
Interventions Research Ethics Committee of London School of Hygiene
and Tropical Medicine, the Institutional Review Board of the Population
Council and Kenyatta National Hospital/University of Nairobi Ethics and
Research Committee. The National Commission for Science, Technology
and Innovation granted the research permit for the study. All respon-
dents provided written informed consent before participating in the
study.4. Results
4.1. Background characteristics
A total of 1512 women (81% of 1866 interviewed in round 3) and
792 women (42% of 1866 interviewed in round 3) had ever used inject-
ables and implants, respectively. Most women were aged 25–39 years,
had no schooling or had incomplete primary level of education, and
wanted no more children. About a third of women who had ever used
injectables were currently using implants, and a fifth of those who had
ever used implants were using injectables in round 3 (Table 1).
Table 2
Proportion of women who reported experiencing bleeding and nonbleeding side effects among current and past users of injectable and implant
Injectable Implant
Current users Past users Current users Past users p value
(n = 558)
%
(n = 954)
%
p value (n = 424)
%
(n = 368)
%
Percentage who experienced any effect on regular menses from using [method] 69.0 76.0 .003 54.5 60.3 .097
The most troubling bleeding effect (n = 385) (n = 725) (n = 231) (n = 222)
No bleeding 36.1 26.2 25.1 18.9
Irregular bleeding 43.9 32.7 b.001 52.4 34.7 b.001
Heavy bleeding 17.7 36.4 20.8 40.5
Others 2.3 4.7 1.7 5.9
Perceived seriousness of the bleeding side effect
Very serious 27.3 57.7 34.6 64.9
Moderately serious 36.9 25.9 b.001 35.5 23.0 b.001
Not serious 35.8 16.4 29.9 12.2
Percentage who sought advice or treatment for bleeding side effects 37.9 52.7 b.001 38.5 63.1 b.001
(n = 558) (n = 954) (n = 424) (n = 368)
Percentage who experienced nonbleeding side effects 31.5 49.5 b.001 31.1 44.0 b.001
Other most troubling other side effects (n = 176) (n = 472) (n = 132) (n = 162)
Headaches 6.3 8.3 6.8 8.0
Dizziness 14.8 15.7 15.9 20.4
Stomach pains/cramps 19.3 17.2 13.6 10.5
Fatigue 8.0 8.9 .098 9.1 15.4 .020
Nausea 3.4 1.7 2.3 0.6
Weight loss 4.6 12.1 8.3 18.5
Weight gain 1.7 3.2 2.3 2.5
Decrease in libido 4.6 4.0 3.8 3.1
Others 37.5 29.0 37.9 21.0
Perceived seriousness of other side effects
Very serious 42.1 65.7 37.1 70.4
Moderately serious 47.7 31.1 b.001 49.2 24.1 b.001
Not serious 10.2 3.2 13.6 5.6
Percentage who sought advice or treatment for other side effects 43.2 52.3 b.001 31.1 63.6 b.001
Table 3
Satisfaction, perceived suitability and the likelihood of future use and duration of intended use reported by current and past users of injectables or implants by type of side effect experi-
enced (percentages)
Current users Past users
Bleeding
problems
only
Nonbleeding
only
Both bleeding
and
nonbleeding
No side
effects
p
value
Bleeding
problems
only
Nonbleeding
only
Bot
bleeding and
nonbleeding
No
side
effects
p
value
Injectables
% satisfied with
method
89.0 81.5 71.1 98.6 b.001 58.0 43.9 23.7 73.0 b.001
% who think method
is suitable for
someone like her
94.1 92.6 87.3 98.0 .003 66.8 65.2 37.9 81.0 b.001
% very or somewhat
likely to use
in the future
NA NA NA NA NA 56.7 57.6 38.7 73.6 b.001
% intending to stop
using the method
within 2 years
19.7 14.8 27.0 23.3 .481 NA NA NA NA NA
Number of women
(N)
236 27 149 146 319 66 406 163
Implants
% satisfied with
method
85.5 69.6 62.8 97.3 b.001 44.6 25.0 19.2 50.0 b.001
% who think
method is
suitable for
someone
like her
85.5 93.5 74.4 95.9 b.001 45.7 43.8 20.0 56.1 b.001
% very or somewhat
likely to use in the
future
NA NA NA NA NA 39.1 28.1 25.4 57.0 b.001
% intending to stop
using the method
within 2 years
21.5 34.8 25.6 21.8 .313 NA NA NA NA NA
Number of women
(N)
145 46 86 147 92 32 130 114
NA, not asked.
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Table 4
Severity, satisfaction, perceived suitability and the likelihood of future use, duration of intended use and care-seekingby specificmenstrual bleedingproblem among current and past users
of injectables and implants (percentages)
Current users p
value
Past users p
value
No
bleeding
Irregular
Bleeding
Heavy
bleeding
No
bleeding
Irregular
Bleeding
Heavy
bleeding
Injectables
% reporting the bleeding effect as ‘very serious’ 22.9 14.6 64.8 b.001 45.8 39.6 80.0 b.001
% who sought treatment 37.1 32.8 49.3 .013 45.3 46.3 62.1 b.001
% satisfied with method 90.7 85.4 56.3 b.001 53.7 51.3 18.6 b.001
% reporting the method is suitable for someone like
them
97.1 94.7 71.8 b.001 62.6 64.2 31.2 b.001
% very or somewhat likely to use in future NA NA NA NA 60.0 56.3 29.5 b.001
% intending to stop using the method within 2 years 19.6 22.9 28.2 .225 NA NA NA
Number of women (N) 139 169 68 190 237 264
Implants
% reporting the bleeding effect as ‘very serious’ 32.8 19.8 70.6 b.001 40.5 39.0 94.0 b.001
% who sought treatment 29.3 32.2 62.8 b.001 52.4 50.7 76.0 .001
% satisfied with method 79.3 86.0 52.9 b.001 54.8 45.5 8.0 b.001
% reporting the method is suitable for someone like
them
82.8 88.4 62.8 .001 42.9 49.4 12.0 b.001
% very or somewhat likely to use in future NA NA NA NA 52.4 44.2 12.0 b.001
% intending to stop using the method within 2 years 10.3 25.8 31.4 .346 NA NA NA
Number of women (N) 58 121 48 42 77 90
4 G. Odwe et al. / Contraception: X 2 (2020) 1000304.2. Experience of bleeding and nonbleeding side effects
The proportion of women reporting bleeding side effects was
slightly higher among past users than current users for both methods
(range 55%–76%) (Table 2). The most commonly reported troubling
bleeding effect among past users of injectables or implants was heavy
bleeding followed by irregular bleeding; the majority considered the
bleeding effect to be very serious. Current users were also concerned
about irregular bleeding. Nonbleeding side effects (mainly dizziness,
pain/cramps, fatigue and weight loss) were also common and more
likely to be reported among past users than current users.
4.3. Experience of side effects and method evaluation
In Table 3, we assess the associations between the experience of
bleeding and nonbleeding side effects and three indicators of women's
overall evaluation of the method: satisfaction, method suitability, and
the likelihood of future use (among past users) and the length of
intended use (among current users).
For past users of injectables, evaluations were strongly related to
side effects. Satisfaction, perceived suitability and likelihood of future
usewere highest amongwomenwho experienced no side effects, inter-
mediate for women who experienced bleeding problems only or
nonbleeding problems only, and lowest for women who experienced
both types of side effect. For current injectable users, positive evalua-
tions were much higher than for past users, and the associations with
side effects were less striking.
The results for past implant users showed similar associations with
side effects as recorded for past injectables users, but the levels of posi-
tive evaluations were slightly lower across all three indicators. Method
evaluation among current users of implants who experienced no side
effects was similarly high as for injectables. There was no clear relation-
ship between side effects and length of intended future.
Reported severity of bleeding, satisfaction, perceived suitability and
likelihood of future use (among past users) were significantly associ-
ated with the type of menstrual bleeding problem (Table 4). Generally,
heavy bleeding had greater consequences than amenorrhea or irregular
bleeding, although the denominators are too small for a confident ver-
dict. For both current and past users of injectables or implants, the pro-
portion of women reporting heavy bleeding as “very serious” was
significantly higher than those who experienced amenorrhea or irregu-
lar bleeding. For past injectables users, the proportion of women satis-
fied or expressing the likelihood of using the method again in thefuture was significantly lower among those who experienced heavy
bleeding than no bleeding or irregular bleeding. The results for past im-
plant users were even more pronounced. The proportion of women
reporting the likelihood of future use was significantly lower among
those who had experienced heavy bleeding than amenorrhea or irregu-
lar bleeding. While heavy bleedingwas less commonly reported among
current users than past users, the effect of this problemonmethod eval-
uationwas similar including the intention to stop usewithin 24months.
4.4. Care-seeking for contraceptive-related menstrual bleeding and
nonbleeding side effects
For both injectables and implants, care-seeking from a healthcare
provider for management of contraceptive-related menstrual bleeding
problemswas low among current users (range 38%–39%) andmoderate
among past users (range 53%–63%). Similar patterns were observed for
nonbleeding side effects (Table 2). Furthermore, care-seeking for
method-related menstrual bleeding irregularities was significantly
higher for women concerned about heavy bleeding than no bleeding
or irregular bleeding.
5. Discussion
The vast body of evidence on contraceptive-related side effects is
mainly drawn from clinical trials, which tend to ignore the implication
of diverse social and cultural contexts. Our study contributes to the lit-
erature on reasons for unmet need for contraceptives by providing a de-
tailed analysis of self-reported method-related side effects and how
these experiences are linked to method-specific attitudes in a setting
characterized by pervasive health-related myths and misconceptions
about methods [22,24].
Our findings show that self-reported method-related menstrual
bleeding problems are high amongboth current andpast users of inject-
ables (range 69%–79%) and only slightly less common for implants
(range 55%–60%). Similar patterns have been observed in several stud-
ies in both high- and low-income settings [1,4,6,25]. Injectable or im-
plant use was associated with changes in regular menstrual patterns
(heavy bleeding, irregular bleeding and amenorrhea) that may influ-
ence method satisfaction, adoption or continuation and, indeed, may
impact women's well-being [6,11].
Nonbleeding side effects were much less commonly reported than
bleeding side effects, and most women reporting these side effects
also reported bleeding problems. Unlike method-related menstrual
5G. Odwe et al. / Contraception: X 2 (2020) 100030bleeding problems, the prevalence of nonbleeding effects was closely
similar for both injectables and implants regardless of use status. Com-
pared with current users, past users of either method were slightly
more likely to report menstrual bleeding or nonbleeding disturbance
but twice as likely to report heavy bleeding as themost troubling effect.
These differences are not surprising, as many past users will have
stopped the method because of side effects or rationalize their discon-
tinuation, leading to overreporting. Moreover, the theory of cognitive
dissonance (the tendency to align beliefs with behavior) [17] may
have resulted in underreporting of side effects among current users.
The same considerations help to explain differences in perceived sever-
ity of side effects — past users for both methods were approximately
twice more likely than current users to regard both menstrual bleeding
and nonbleeding side effects as “very serious.” Nevertheless, even
among current users, approximately one third judged both menstrual
and nonmenstrual side effects to be very serious. Clearly, willingness
to continue to use a method does not imply that there are no problems
or concerns. Some women may express serious dissatisfaction
with bleeding and other side effects disturbance and opt to discontinue
or switch to less effective methods, while others may tolerate these
problems as a trade-off for the benefit of effective pregnancy-
prevention [26,27].
The major contribution of the analysis concerned the links between
experience of side effects and attitudes towards the method. The expe-
rience of either type of side effect reduces positive evaluations of the
method, but the conjunction of both types has particularly pronounced
consequences. The likelihood of future use is an especially important in-
dicator given that much unmet need for family planning stems from
discontinued users [16]. Satisfaction tends to be lower among women
who were experiencing both types of side effects than those reporting
no effects. Notably, attitudes among past users of implants were less
positive than attitudes among past users of injectables. We speculate
that women who stop implant use are more deeply dissatisfied with
themethod than is the case for thosewho stop using injectables because
discontinuation of implants requires a conscious effort, whereas discon-
tinuation of injectables requires nothing more than inertia [9].
Because of the detailed information collected about menstrual prob-
lems, we contrasted the links between different types of menstrual
problems and attitudes towards methods. The results were clear-cut.
Heavy bleeding was much more likely to be regarded as very serious
than irregular or no bleeding, and it wasmuchmore strongly associated
with negative evaluations of the method. These results were consistent
for past and current users of both methods.
Despite high prevalence of contraceptive-related menstrual prob-
lems, care-seeking from a healthcare provider for management of the
conditions was low among current users (less than 40%) and moderate
among past users (range 53%–63%). Care-seeking for side effects was
higher among past users than current users perhaps because the former
were more likely to have seen a provider to discontinue or switch
methods. Low care-seeking may also be due to factors such as difficul-
ties in accessing care, lack of awareness of treatment options or fear
due to stigma [18,28]. An important finding of our study is that care-
seeking was associated with the type of menstrual problems, being
more likely among women experiencing heavy bleeding than no or ir-
regular bleeding (for current and past users of both methods). It
seems likely that heavy or prolonged bleeding is considered a greater
health hazard than other forms of menstrual changes, which propels
women to seek care [12,15].
The study has some limitations. Information on bleeding irregulari-
ties was self-reported without clinical verification. There is a potential
for response bias; reported bleeding problems could be due to a nocebo
effect (negative expectations which lead to inflated reports) [29,30],
lack of understanding about normal bodily fluctuations or poor compli-
ance [31]. However, the findings are consistentwith evidence from pre-
vious studies. Findings are based on past users of injectables and
implants and do not account for method(s) participants were using atthe time of survey which may influence perceptions about these two
methods. The analysis is descriptive and cross-sectional based on data
from a rural setting; hence, the results may not be generalized to
other settings. Nonetheless, our study provides a detailed quantitative
analysis of the links between experiences of bleeding and nonbleeding
side effects vis-à-vis method evaluation.
In conclusion, overall method satisfaction, perception of method
suitability and the likelihood of future use (past users) were statistically
significantly associated with self-reported type of menstrual bleeding.
Heavy bleeding hadmore serious consequences than other types of dis-
turbances. The findings suggest a need for strengthening programs on
counseling and information on contraceptive side effects including
bleeding and nonbleeding side effects to improve method satisfaction
and reduce discontinuation.Acknowledgments
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